
|Articles|September 7, 2000
Tentative FDA Approval for Generic Version of Taxol
Advertisement
(MIAMI, FL)Ivax, Corporation has received tentative approval from the Food and Drug Administration (FDA) for paclitaxel, a generic form of the cancer drug Taxol, made by Bristol-Myers Squibb Company. However, due to a pending lawsuit and patent litigation against Bristol-Myers, it may be as long as 30 months until Ivax can begin selling the new drug. If Ivax obtains final clearance to sell the generic form of Taxol, it is entitled to 180 days of marketing exclusivity for having been the first to file with the FDA. For more information, visit www.fda.org.
Newsletter
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Advertisement
Advertisement
Advertisement
Trending on Infection Control Today
1
Influenza D and Canine Coronavirus: Why Underrecognized Animal Viruses May Be the Next Respiratory Threat
2
What Is Effective Preparedness for Emerging Respiratory Viruses? Shazia Irum, MSC, MBA, RN, CIC, CPHQ, FAPIC, answers
3
Dialysis Infection Risks and Prevention Strategies: A Q&A With NP Leader Octavia “Tavi” Schlueter, MSN, RN, CPNP-PC, PMHS
4
Continuous Photohydrolysis Disinfection Cuts MDROs, COVID-19, and Hospital Transfers in Long-Term Care, Study Finds
5




